Quality Improvements in Lung Cancer Surgery and Tumor Pathology May Extend Survival Postsurgery
““Over the past 15 years, a quality improvement initiative in the heart of the Mississippi Delta has made stepped progress to change the status quo for lung cancer outcomes in this high-risk population. Their consistent efforts led the 120-day mortality rate after surgery to be cut in half and improvements in both 3- and 5-year overall survival,” emphasized Fumiko Chino, MD, a radiation oncologist at The University of Texas MD Anderson Cancer Center, Houston.”
New Mount Sinai Research Brings Hope for Small Cell Lung Cancer Patients
“New York, NY (September 30, 2024) Researchers at the Icahn School of Medicine at Mount Sinai have made a promising breakthrough in the treatment of small cell lung cancer (SCLC). Their study, published in Science Advances, on September 27 and titled “ATR Inhibition Activates Cancer Cell cGAS/STING-Interferon Signaling and Promotes Anti-Tumor Immunity in Small Cell Lung Cancer,” presents an exciting new approach that offers hope to patients with this challenging disease.”
The impact of family cancer history on tumor metabolism and prognosis in patients with non-small cell lung cancer
“Non-small cell lung cancer (NSCLC) is a leading cause of cancer-related mortality, and the role of family cancer history in disease progression and treatment response remains underexplored. This study aims to investigate the influence of family tumor history on disease-free survival, tumor metabolism, and treatment response in NSCLC patients.”
Trial shows timing matters when adding immunotherapy to chemoradiation for limited-stage small cell lung cancer
“People with limited-stage small cell lung cancer may benefit from adding immunotherapy to chemoradiation, but not if both treatments are given at the same time, new research finds. The results suggest that the timing of when immunotherapy is given plays a key role in its ability to extend survival.”
Survival of lung cancer patients according to screening eligibility using Korean Lung Cancer Registry 2014–2016
“This study assessed survival for lung cancer patients meeting criteria for the National Lung Cancer Screening Program in Korea launched in 2019 and updated guideline reported by the US Preventive Service Task Force (USPSTF).”
J&J lung cancer drug combo had superior progression-free survival in study
“Patients who took Johnson & Johnson (NYSE:JNJ) drugs Rybrevant and Leclaza in combination to treat EGFR-mutated non-small cell lung cancer had a longer progression-free survival period than those who took AstraZeneca’s (AZN) Tagrisso, according to a new study.”
American Lung Association Campaign Aims to Address Lack of Diversity in Clinical Trials, Improve Lung Cancer Care for Hispanic Individuals
“CHICAGO, Sept. 26, 2024 /PRNewswire/ — In the past decade, clinical trials have contributed to rapidly advancing research, which has led to more individuals living with lung cancer exceeding the five-year survival rate than ever before. Unfortunately, this progress has not been shared equally amongst the populations facing high lung cancer burdens. That’s why the American Lung Association is expanding its work through the Awareness, Trust and Action program to educate Hispanic individuals about clinical trials and encourage them to speak with their healthcare provider about their treatment options.”
FDA approves osimertinib for locally advanced, unresectable (stage III) non-small cell lung cancer following chemoradiation therapy
“On September 25, 2024, the Food and Drug Administration approved osimertinib (Tagrisso, AstraZeneca Pharmaceuticals) for adult patients with locally advanced, unresectable (stage III) non-small cell lung cancer (NSCLC) whose disease has not progressed during or following concurrent or sequential platinum-based chemoradiation therapy and whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test.”
Video:
Advancing Lung Cancer Screening: Detection and Management of Early-Stage Lung Cancer
“Tune in to this expert-led, on-demand video for a discussion on the latest recommendations, guidelines, and best practices related to lung cancer screening, and management of early-stage disease. Insights from previous peer-to-peer discussions on lung cancer screening barriers across primary care clinics will also be discussed.”
